ACIU

Company Overview — What Does AC Immune SA Do?

AC Immune SA, a clinical stage biopharmaceutical company, discovers, designs, and develops medicines and diagnostic products for the prevention and treatment of neurodegenerative diseases associated with protein misfolding. Its SupraAntigen and Morphomer platforms are designed to generate vaccines, antibodies, and small molecules, which selectively interact with misfolded proteins that are common in a range of neurodegenerative diseases. The company is developing Crenezumab, a humanized, conformation-specific monoclonal antibody, which is in Phase II clinical prevention trial for the treatment of Alzheimer's disease (AD). It is also developing ACI-24, an anti-Abeta vaccine candidate that is in Phase II clinical study for AD, as well as completed Phase Ib clinical study for Down syndrome; ACI-35, an anti-Tau vaccine candidate that has completed Phase Ib clinical study; and Tau- positron emission tomography (PET) imaging tracer, which is in Phase II clinical study. In addition, the company is researching and developing small molecule Tau aggregation inhibitors for AD and NeuroOrphan indications. Further, it has discovery and preclinical stage molecules targeting range of neurodegenerative diseases, which include diagnostics targeting TDP-43, alpha-synuclein, and NLRP3. AC Immune SA has license agreements and collaborations with Genentech, Inc.; Biogen International GmbH; Janssen Pharmaceuticals, Inc.; Life Molecular Imaging SA; Eli Lilly and Company; and WuXi Biologics. The company was incorporated in 2003 and is headquartered in Lausanne, Switzerland. AC Immune SA (ACIU) is classified as a micro-cap stock in the Healthcare sector, specifically within the Pharmaceutical Products industry. The company is led by CEO Andrea Pfeifer and employs approximately 140 people. With a market capitalization of $284M, ACIU is one of the notable companies in the Healthcare sector.

AC Immune SA (ACIU) Stock Rating — Reduce (April 2026)

As of April 2026, AC Immune SA receives a Reduce rating with a composite score of 35.0/100 and 2 out of 5 stars from the Blank Capital Research quantitative model.ACIU ranks #3,423 out of 4,446 stocks in our coverage universe. Within the Healthcare sector, AC Immune SA ranks #527 of 838 stocks, placing it in the lower half of its Healthcare peers. The rating is generated by a multi-factor model that weighs quality (30%), momentum (25%), value (15%), investment (10%), stability (10%), and short interest (10%).

ACIU Stock Price and 52-Week Range

AC Immune SA (ACIU) currently trades at $3.42. The stock gained $0.02 (0.6%) in the most recent trading session. The 52-week high for ACIU is $4.00, which means the stock is currently trading -14.5% from its annual peak. The 52-week low is $1.43, putting the stock 139.2% above its annual trough. Recent trading volume was 128K shares, suggesting relatively thin trading activity.

Is ACIU Overvalued or Undervalued? — Valuation Analysis

AC Immune SA (ACIU) carries a value factor score of 19/100 in the Blank Capital model, signaling premium valuation that prices in significant future growth. The price-to-book ratio stands at 2.56x, versus the sector average of 2.75x. The price-to-sales ratio is 2.63x, compared to 1.66x for the average Healthcare stock.

At current multiples, AC Immune SA trades at a premium to most Healthcare peers. This elevated valuation may be justified if the company can sustain above-average growth rates and profitability, but it also creates downside risk if earnings disappoint expectations.

AC Immune SA Profitability — ROE, Margins, and Quality Score

AC Immune SA (ACIU) earns a quality factor score of 35/100, signaling below-average profitability metrics relative to the broader market. The return on equity (ROE) is -181.4%, compared to the Healthcare sector average of -43.5%, which is below typical expectations for high-quality companies. Return on assets (ROA) comes in at -88.2% versus the sector average of -33.1%.

On a margin basis, AC Immune SA reports gross margins of 100.0%, compared to 71.5% for the sector. The operating margin is -191.8% (sector: -66.1%). Net profit margin stands at -186.4%, versus -58.7% for the average Healthcare stock. Profitability is below benchmark levels, which may reflect industry headwinds, elevated reinvestment, or structural challenges.

ACIU Debt, Balance Sheet, and Financial Health

AC Immune SA has a debt-to-equity ratio of 4.0%, compared to the Healthcare sector average of 32.0%. The low leverage indicates a conservative balance sheet with significant financial flexibility. Total debt on the balance sheet is $5M. Cash and equivalents stand at $40M.

ACIU has a beta of 1.04, meaning it is roughly in line with the broader market in terms of price volatility. The stability factor score for AC Immune SA is 38/100, suggesting elevated price swings that may be unsuitable for conservative portfolios.

AC Immune SA Revenue and Earnings History — Quarterly Trend

In TTM 2026, AC Immune SA reported revenue of $30M and earnings per share (EPS) of $-0.56. Net income for the quarter was $-56M. Gross margin was 100.0%. Operating income came in at $-58M.

In FY 2024, AC Immune SA reported revenue of $30M and earnings per share (EPS) of $-0.56. Net income for the quarter was $-56M. Gross margin was 100.0%. Revenue grew 71.0% year-over-year compared to FY 2023. Operating income came in at $-58M.

In FY 2023, AC Immune SA reported revenue of $18M and earnings per share (EPS) of $-0.76. Net income for the quarter was $-65M. Gross margin was 100.0%. Revenue grew 313.5% year-over-year compared to FY 2022. Operating income came in at $-64M.

In FY 2022, AC Immune SA reported revenue of $4M and earnings per share (EPS) of $-0.92. Net income for the quarter was $-77M. Gross margin was 100.0%. Operating income came in at $-77M.

Over the past 8 quarters, AC Immune SA has demonstrated a growth trajectory, with revenue expanding from $7M to $30M. Investors analyzing ACIU stock should weigh these quarterly trends alongside the valuation and quality metrics discussed above.

ACIU Dividend Yield and Income Analysis

AC Immune SA (ACIU) does not currently pay a dividend. This is common among smaller companies in the Pharmaceutical Products industry that prefer to reinvest cash flows into business expansion rather than returning capital to shareholders. Income-focused investors looking for Healthcare dividend stocks may want to explore other Healthcare stocks or use the stock screener to filter by dividend yield.

ACIU Momentum and Technical Analysis Profile

AC Immune SA (ACIU) has a momentum factor score of 59/100, reflecting neutral trend characteristics. The stock is neither significantly outperforming nor underperforming the broader market on a momentum basis. The investment factor score is 28/100, which measures capital allocation efficiency and asset growth patterns. The short interest score of 4/100 signals elevated short interest, which can indicate bearish sentiment among institutional investors.

ACIU vs Competitors — Healthcare Sector Ranking and Peer Comparison

Within the Healthcare sector, AC Immune SA (ACIU) ranks #527 out of 838 stocks based on the Blank Capital composite score. This places ACIU in the lower half of all Healthcare stocks in our coverage universe. Key competitors and sector peers include ASTRAZENECA PLC (AZN) with a score of 61.4/100, Sol-Gel Technologies Ltd. (SLGL) with a score of 56.6/100, VIEMED HEALTHCARE, INC. (VMD) with a score of 53.4/100, Innoviva, Inc. (INVA) with a score of 52.7/100, and JOHNSON & JOHNSON (JNJ) with a score of 51.7/100.

Comparing ACIU against the S&P 500 benchmark is also instructive for understanding relative performance. Investors can view the full ACIU vs S&P 500 (SPY) comparison to assess how AC Immune SA stacks up against the broader market across all factor dimensions.

ACIU Next Earnings Date

No upcoming earnings date has been announced for AC Immune SA (ACIU) at this time. Check the earnings calendar for the latest scheduling updates across all stocks in our coverage universe.

Should You Buy ACIU? — Investment Thesis Summary

The quantitative profile for AC Immune SA suggests caution. The quality score of 35/100 flags below-average profitability. The value score of 19/100 indicates premium valuation. High volatility (stability score 38/100) increases portfolio risk.

In summary, AC Immune SA (ACIU) earns a Reduce rating with a composite score of 35.0/100 as of April 2026. The rating is derived from the Blank Capital Research methodology, which combines six factor dimensions into a single quantitative ranking. Investors should consider these quantitative signals alongside their own fundamental research, risk tolerance, and investment time horizon before making buy or sell decisions on ACIU stock.

Related Resources for ACIU Investors

Explore more research and tools: ACIU vs S&P 500 comparison, top Healthcare stocks, stock screener, our methodology, quality factor explained, value factor explained, momentum factor explained. Compare ACIU head-to-head with peers: ACIU vs AZN, ACIU vs SLGL, ACIU vs VMD.